0.9402
price down icon0.58%   -0.0147
 
loading
Precedente Chiudi:
$0.9549
Aprire:
$0.9782
Volume 24 ore:
3,071
Relative Volume:
0.02
Capitalizzazione di mercato:
$39.51M
Reddito:
-
Utile/perdita netta:
$-31.37M
Rapporto P/E:
-0.6538
EPS:
-1.438
Flusso di cassa netto:
$-4.23M
1 W Prestazione:
+0.30%
1M Prestazione:
-5.06%
6M Prestazione:
-35.85%
1 anno Prestazione:
-17.45%
Intervallo 1D:
Value
$0.9305
$0.99
Intervallo di 1 settimana:
Value
$0.92
$0.99
Portata 52W:
Value
$0.90
$2.45

Mira Pharmaceuticals Inc Stock (MIRA) Company Profile

Name
Nome
Mira Pharmaceuticals Inc
Name
Telefono
813-369-5150
Name
Indirizzo
1200 BRICKELL AVENUE, MIAMI
Name
Dipendente
2
Name
Cinguettio
Name
Prossima data di guadagno
2026-08-13
Name
Ultimi documenti SEC
Name
MIRA's Discussions on Twitter

Compare MIRA vs LLY, JNJ, ABBV, MRK, NVS

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
MIRA icon
MIRA
Mira Pharmaceuticals Inc
0.9402 39.77M 0 -31.37M -4.23M -1.438
LLY icon
LLY
Lilly Eli Co
1,235.99 1.07T 72.25B 25.28B 10.37B 27.78
JNJ icon
JNJ
Johnson Johnson
268.21 611.36B 96.36B 21.04B 17.80B 8.6488
ABBV icon
ABBV
Abbvie Inc
259.96 444.60B 62.82B 3.60B 19.98B 2.0274
MRK icon
MRK
Merck Co Inc
128.63 317.37B 65.51B 8.93B 14.12B 3.5532
NVS icon
NVS
Novartis Ag Adr
157.56 299.04B 54.66B 13.58B 16.05B 7.0171

Mira Pharmaceuticals Inc Borsa (MIRA) Ultime notizie

pulisher
Jun 29, 2026

MIRA Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director MacPherson Edward Cloustonmoomoo - Moomoo

Jun 29, 2026
pulisher
Jun 29, 2026

MIRA Pharmaceuticals, Inc.(NasdaqCM:MIRA) added to Russell Microcap Growth Benchmark Index - marketscreener.com

Jun 29, 2026
pulisher
Jun 28, 2026

MIRA Pharmaceuticals, Inc.(NasdaqCM: MIRA) added to Russell 3000E Index - marketscreener.com

Jun 28, 2026
pulisher
Jun 28, 2026

MIRA SEC FilingsMira Pharma 10-K, 10-Q, 8-K Forms - Stock Titan

Jun 28, 2026
pulisher
Jun 27, 2026

Price to earnings forward of MIRA Pharmaceuticals, Inc. – NASDAQ:MIRA - TradingView

Jun 27, 2026
pulisher
Jun 26, 2026

Enterprise value to revenue forward of MIRA Pharmaceuticals, Inc. – NASDAQ:MIRA - TradingView

Jun 26, 2026
pulisher
Jun 26, 2026

MIRA Pharmaceuticals Reports New Preclinical Data Demonstrating Mira-55's Differentiated Mechanism of Action and Anxiolytic Activity Relative to THC - Black Hills Pioneer

Jun 26, 2026
pulisher
Jun 26, 2026

MIRA Pharmaceuticals, Inc. Actuals & Estimates (FWB:K6S) - TradingView

Jun 26, 2026
pulisher
Jun 25, 2026

MIRA Pharmaceuticals, Inc. Actuals & Estimates (MUN:K6S) - TradingView

Jun 25, 2026
pulisher
Jun 25, 2026

MIRA Pharmaceuticals, Inc. Actuals & Estimates (TRADEGATE:K6S) - TradingView

Jun 25, 2026
pulisher
Jun 25, 2026

K6S Forecast — Price Target — Prediction for 2027 - TradingView

Jun 25, 2026
pulisher
Jun 25, 2026

MIRA Forecast — Price Target — Prediction for 2027 - TradingView

Jun 25, 2026
pulisher
Jun 25, 2026

MIRA Flat at Open - Baystreet.ca

Jun 25, 2026
pulisher
Jun 25, 2026

MIRA Pharmaceuticals (NASDAQ:MIRA) Reports Positive Preclinical Data for Mira-55 in Chronic Inflammatory Pain - grafa.com

Jun 25, 2026
pulisher
Jun 25, 2026

Mira Pharmaceuticals reports preclinical data on pain drug candidate - Investing.com

Jun 25, 2026
pulisher
Jun 25, 2026

MIRA Pharmaceuticals Advances Mira-55 for Chronic Pain Relief - GuruFocus

Jun 25, 2026
pulisher
Jun 25, 2026

Mira Pharmaceuticals reports preclinical data on pain drug candidate By Investing.com - Investing.com Australia

Jun 25, 2026
pulisher
Jun 25, 2026

MIRA Unveils Differentiated Preclinical Data for Mira-55 - TipRanks

Jun 25, 2026
pulisher
Jun 25, 2026

MIRA’s Mira-55 eases anxiety in preclinical tests, unlike THC - Stock Titan

Jun 25, 2026
pulisher
Jun 25, 2026

MIRA reports preclinical Mira-55 data showing distinct mechanism, anxiolytic activity vs THC - TradingView

Jun 25, 2026
pulisher
Jun 25, 2026

MIRA Pharmaceuticals (NASDAQ: MIRA) highlights differentiated Mira-55 preclinical profile vs. THC - Stock Titan

Jun 25, 2026
pulisher
Jun 22, 2026

Mira Pharmaceuticals Inc (MIRA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey

Jun 22, 2026
pulisher
Jun 19, 2026

MIRA Pharmaceuticals Submits Phase 2a Clinical Trial Protocol to FDA for Ketamir-2 in Chemotherapy-Induced Peripheral Neuropathy - ACCESS Newswire

Jun 19, 2026
pulisher
Jun 18, 2026

MIRA Technical Analysis | Trend, Signals & Chart Patterns - ChartMill

Jun 18, 2026
pulisher
Jun 18, 2026

Mira Pharmaceuticals Inc (MIRA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey

Jun 18, 2026
pulisher
Jun 18, 2026

Telomir Pharmaceuticals Inc (TELO) Institutional Confidence - TradingKey

Jun 18, 2026
pulisher
Jun 17, 2026

Telomir Pharmaceuticals Inc (TELO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey

Jun 17, 2026
pulisher
Jun 17, 2026

Mira Pharmaceuticals Inc (MIRA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey

Jun 17, 2026
pulisher
Jun 17, 2026

Mira Pharmaceuticals Inc (MIRA) Institutional Confidence - TradingKey

Jun 17, 2026
pulisher
Jun 17, 2026

Mira Pharmaceuticals Inc (MIRA) Valuation: PE, PB & Fair Value Analysis - TradingKey

Jun 17, 2026
pulisher
Jun 17, 2026

Mira Pharmaceuticals Inc (MIRA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey

Jun 17, 2026
pulisher
Jun 17, 2026

Mira Pharmaceuticals Inc (MIRA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey

Jun 17, 2026
pulisher
Jun 17, 2026

Mira Pharmaceuticals Inc (MIRA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey

Jun 17, 2026
pulisher
Jun 17, 2026

Mira Pharmaceuticals Inc (MIRA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey

Jun 17, 2026
pulisher
Jun 17, 2026

MIRA Pharmaceuticals submits Phase 2a trial for Ketamir-2 - grafa.com

Jun 17, 2026
pulisher
Jun 17, 2026

MIRA Pharmaceuticals submits Phase 2a trial protocol for CIPN By Investing.com - Investing.com South Africa

Jun 17, 2026
pulisher
Jun 17, 2026

MIRA Pharmaceuticals submits Phase 2a trial protocol for CIPN - Investing.com UK

Jun 17, 2026
pulisher
Jun 17, 2026

MIRA Advances Ketamir-2 Into FDA-Accepted Phase 2a Trial - TipRanks

Jun 17, 2026
pulisher
Jun 17, 2026

Phase 2a CIPN trial protocol for Ketamir-2 accepted, MIRA (NASDAQ: MIRA) - Stock Titan

Jun 17, 2026
pulisher
Jun 17, 2026

Chemo nerve damage leaves millions without an approved drug; MIRA plans Ketamir-2 trial - Stock Titan

Jun 17, 2026
pulisher
Jun 16, 2026

MIRA News | MIRA PHARMACEUTICALS INC (NASDAQ:MIRA) - ChartMill

Jun 16, 2026
pulisher
Jun 16, 2026

MIRA Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Whalen Matthew Pratt - Moomoo

Jun 16, 2026
pulisher
Jun 15, 2026

MIRA PHARMACEUTICALS (MIRA) director granted 50,000 stock options award - Stock Titan

Jun 15, 2026
pulisher
Jun 15, 2026

MIRA Pharmaceuticals (MIRA) grants director 50,000 stock options at $0.94 - Stock Titan

Jun 15, 2026
pulisher
Jun 15, 2026

MIRA Pharmaceuticals (MIRA) grants director 50,000 stock options - Stock Titan

Jun 15, 2026
pulisher
Jun 10, 2026

MIRA Pharmaceuticals Inc. (MIRA) Edges Higher: Navigating Key Levels in a Volatile SectorGolden Cross - newsline.com

Jun 10, 2026
pulisher
Jun 09, 2026

MIRA Pharmaceuticals Appoints New Fractional Chief Financial Officer - The Globe and Mail

Jun 09, 2026
pulisher
Jun 09, 2026

MIRA PHARMACEUTICALS (MIRA) CFO Andriy Mushak listed as insider in Form 3 - Stock Titan

Jun 09, 2026
pulisher
Jun 08, 2026

Mira Pharmaceuticals appoints Andriy Mushak as fractional CFO By Investing.com - Investing.com Nigeria

Jun 08, 2026
pulisher
Jun 08, 2026

Mira Pharmaceuticals appoints Andriy Mushak as fractional CFO - Investing.com

Jun 08, 2026
pulisher
Jun 08, 2026

Mira PharmaceuticalsAlan Weichselbaum To Step Down As CFO Effective June 6, 2026SEC Filing - TradingView

Jun 08, 2026

Mira Pharmaceuticals Inc Azioni (MIRA) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
PFE PFE
$24.21
price up icon 1.95%
$134.16
price up icon 3.70%
$374.04
price up icon 0.09%
NVO NVO
$50.10
price up icon 1.77%
AZN AZN
$192.33
price up icon 1.33%
NVS NVS
$157.23
price up icon 1.14%
Capitalizzazione:     |  Volume (24 ore):